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OBJECTIVES: Respiratory syncytial virus infection (RSV) is a
leading cause of rehospitalization in high-risk infants such as pre-
mature and bronchopulmonary dysplasia (BPD). Palivizumab is
effective for prevention of serious RSV illness in such high-risk
infants but cost-effectiveness of palivizumab in Japan has not
been reported. The aim of this study was to assess the cost-
effectiveness of palivizumab for prevention of rehospitalization
due to RSV infection in premature infants and such with BPD in
Japan. METHODS: A decision tree was constructed to estimate
the cost-effectiveness of palivizumab in Japan. Probabilities of
rehospitalization, death and asthma as sequelae were obtained
from published studies. Drug cost of palivizumab was set based
on the Japanese drug price list. Other cost parameter was
obtained from published literature in the Japanese setting. We
employed a payer’s perspective and only considered direct
medical cost. The discount rate employed was 3%. RESULTS:
The expected cost was $7,665 (JPY 896,752) in the palivizumab
and $328 (JPY 38,373) in the no prophylaxis, respectively.
QALYs was 30.392 in the palivizumab and 30.200 in the no pro-
phylaxis, respectively. The incremental cost-effectiveness ratio
(ICER) of palivizumab was $38,312 (M JPY 4.48). Sensitivity
analyses showed that the results are more sensitive to the hospi-
talization rate of palivizumab and less sensitive to the cost 
of hospitalization and asthma. CONCLUSION: ICER of
palivizumab in Japan was similar to results in other countries.
This study suggested that Palivizumab for prophylaxis of rehos-
pitalization due to RSV infection in premature infants and such
with BPD appeared to be cost-effective in Japan.
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OBJECTIVES: To compare ﬁrst-order Monte Carlo microsimu-
lation of individual patients to a cohort approach in modeling
the cost-effectiveness of antiretroviral therapy (ART) in HIV
infection, and to validate the two models against a published
model (CEPAC). METHODS: A published CEPAC study com-
pared ART guided by resistance testing to empirical ART in
treatment-naive patients. We analyzed the reported input data,
using a newly-developed microsimulation model (ATHOS) and
a simpliﬁed cohort version (CM) and compared the results. Using
cohort baseline characteristics from a large clinical trial (ACTG
384), the models estimated lifetime discounted (3%) costs and
quality-adjusted life years (QALYs) in treatment-naive patients.
Disease progression depended upon CD4 cell count, viral 
load set point, treatment line (5 allowed), response, age, and 
incidence of opportunistic infections. ATHOS used tracker 
variables to record the evolution of these variables, and modify
progression probabilities accordingly. In contrast, the CM
required additional Markov states and that each line of therapy
be run individually in reverse sequence, embedding outcomes of
line x into line x-1 as terminal tolls. RESULTS: Estimated 
discounted mean lifetime costs per patient on ART guided by
resistance testing were as follows. ATHOS: $331,000; CV:
$433,600 (CEPAC: $338,600). Mean discounted QALYs 
were ATHOS: 13.86; CV: 14.99 (CEPAC: 14.11). CONCLU-
SION: For treatment-naïve patients, ATHOS generated QALY
and cost estimates comparable to an established and frequently
published model of ART, but it produced rather different esti-
mates from the CM. Though the cohort approach requires less
computing time and allows probabilistic analysis of uncertainty,
it seems that the limitations outweigh the beneﬁts when model-
ing sequential lines of therapy for treatment-naïve HIV patients.
In this case study, microsimulation allowed important prog-
nostic factors to be more adequately represented than was fea-
sible with a cohort approach, and thus avoided oversimplifying
assumptions.
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OBJECTIVES: The effect of new products on health care
resource utilization is often evaluated in randomized clinical
trials. This presentation assesses the strengths and limitations of
these trial based analyses. METHODS: Merck Research Labo-
ratories recently collected health care resource use data in two
large scale vaccine trials. The Shingles Prevention Study (SPS) fol-
lowed nearly 40,000 subjects to determine the impact of a zoster
vaccine on the incidence and severity of herpes zoster in people
≥60 years old. The Rotavirus Efﬁcacy and Safety Trial (REST)
followed nearly 70,000 infants to determine the impact of a
rotavirus vaccine on the incidence and severity of rotavirus gas-
troenteritis. In both trials, Poisson regression was used to
compare the rates of nonprotocol mandated health care encoun-
ters in the vaccine and placebo groups. RESULTS: In the SPS the
reduction in the rate of nonprotocol mandated health care
encounters was 64.7% (95% CI: 31.2, 81.9) for all subjects with
herpes zoster and 78.3% (95% CI: 48.2, 90.9) for subjects with
postherpetic neuralgia. In REST the reduction in the rate of hos-
pitalizations and emergency department visits was 94.5% (95%
CI: 91.2, 96.6) in the ﬁrst two years after vaccination. CON-
CLUSION: The trial design did affect the rates of health care
encounters observed relative to epidemiology studies. However,
the effect of the vaccines on the relative reductions in resource
use were consistent with other endpoints measuring the impact
of the vaccines on the burden of illness.
